Labrys Biologics Secures $31,000,000 Series A Funding Round
- Feed Type
- Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=9b242101-e825-49c6-97a5-73d55dfd0721&Preview=1 - Date
1/4/2013 - Company Name
Labrys Biologics - Mailing Address
1700 Owens Street San Francisco, CA 94158 - Company Description
Labrys Biologics is a private, venture-financed development stage biotechnology company focused on treatments for chronic migraine. Labrys’ lead candidate, RN-307, is an anti-CGRP monoclonal antibody for the treatment of chronic migraine slated to enter Phase 2 clinical trials in 2013. - Website
Undisclosed
- Transaction Type
Venture Equity - Transaction Amount
$31,000,000 - Transaction Round
Series A - Proceeds Purposes
Under the terms of the agreement with Pfizer, Labrys acquired worldwide rights to RN-307. - M&A Terms
- Venture Investor
venBio - Venture Investor
Canaan Partners - Venture Investor
InterWest Partners - Venture Investor
Sofinnova Ventures
